Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 9/20 | 0.70 |
| ▸ | AKT2 | P31751 | 3/20 | 0.70 |
| ▸ | AKT3 | Q9Y243 | 3/20 | 0.70 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.70 |
| ▸ | PRKCB | P05771 | 2/20 | 0.70 |
| ▸ | PRKCA | P17252 | 2/20 | 0.70 |
| ▸ | PRKACA | P17612 | 2/20 | 0.70 |
| ▸ | PRKACB | P22694 | 2/20 | 0.70 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.70 |
| ▸ | PKN1 | Q16512 | 2/20 | 0.70 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.70 |
| ▸ | CIT | O14578 | 1/20 | 0.70 |
| ▸ | SGK1 | O00141 | 1/20 | 0.43 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.43 |
| ▸ | LATS1 | O95835 | 1/20 | 0.43 |
| ▸ | PRKCG | P05129 | 1/20 | 0.43 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.43 |
| ▸ | PRKCH | P24723 | 1/20 | 0.43 |
| ▸ | MARK3 | P27448 | 1/20 | 0.43 |
| ▸ | PRKCI | P41743 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2301059 | 1.00 | AKT1 (0.70) | AKT1AKT2AKT3ROCK2PRKCB | |
| SCHEMBL28526514 | 1.00 | AKT1 (0.70) | AKT1AKT2AKT3ROCK2PRKCB | |
| SCHEMBL2302980 | 0.91 | AKT1 (0.56) | AKT1AKT2AKT3ROCK2PRKCB | |
| SCHEMBL2300200 | 0.91 | AKT1 (0.56) | AKT1AKT2AKT3ROCK2PRKCB | |
| SCHEMBL28523203 | 0.91 | AKT1 (0.56) | AKT1AKT2AKT3ROCK2PRKCB | |
| SCHEMBL2300062 | 0.90 | AKT1 (0.56) | AKT1AKT2AKT3ROCK2PRKCB | |
| SCHEMBL2301203 | 0.90 | AKT1 (0.56) | AKT1AKT2AKT3ROCK2PRKCB | |
| SCHEMBL2302178 | 0.90 | AKT1 (0.56) | AKT1AKT2AKT3ROCK2PRKCB | |
| SCHEMBL2302214 | 0.89 | AKT1 (0.55) | AKT1AKT2AKT3ROCK2PRKCB | |
| SCHEMBL2299884 | 0.89 | AKT1 (0.55) | AKT1AKT2AKT3ROCK2PRKCB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8592475-B2 | Inhibitors of Akt activity | GLAXOSMITHKLINE LLC (US) | 2013-11-26 | — | — | US | claimed |
| US-20110196009-A1 | INHIBITORS OF Akt ACTIVITY | SMITHKLINE BEECHAM CORPORATION | 2011-08-11 | — | — | US | claimed |
| US-20210379021-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | RACE ONCOLOGY LTD (AU) | 2021-12-09 | — | — | US | disclosed |
| US-11147800-B2 | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2021-10-19 | — | — | US | disclosed |
| US-11135201-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2021-10-05 | — | — | US | disclosed |
| CN-113365610-A | Methods of making and delivering bisantrene formulations | 现代化制药公司 | 2021-09-07 | — | — | CN | disclosed |
| EP-3860575-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | Race Oncology Ltd. (AU) | 2021-08-11 | — | — | EP | disclosed |
| CN-112472699-A | Combination methods for improving the therapeutic benefit of bisantrene and derivatives | 种族肿瘤学公司 | 2021-03-12 | — | — | CN | disclosed |
| US-20200163939-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | SG CREDIT PARTNERS, INC. | 2020-05-28 | — | — | US | disclosed |
| US-20200163940-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | RACE ONCOLOGY LTD. (AU) | 2020-05-28 | — | — | US | disclosed |
| WO-2020072948-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | RACE ONCOLOGY LTD. (AU) | 2020-04-09 | — | — | WO | disclosed |
| EP-3024456-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE | Update Pharma Inc. (US) | 2016-06-01 | — | — | EP | disclosed |
| EP-3024457-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE | Update Pharma Inc. (US) | 2016-06-01 | — | — | EP | disclosed |
| WO-2015013581-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE | UPDATE PHARMA INC. (US) | 2015-01-29 | — | — | WO | disclosed |
| WO-2015013579-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE | UPDATE PHARMA INC. (US) | 2015-01-29 | — | — | WO | disclosed |
| US-8592475-B2 | Inhibitors of Akt activity | GLAXOSMITHKLINE LLC (US) | 2013-11-26 | — | — | US | disclosed |
| US-20110196009-A1 | INHIBITORS OF Akt ACTIVITY | SMITHKLINE BEECHAM CORPORATION | 2011-08-11 | — | — | US | disclosed |
| US-20110196009-A1 | INHIBITORS OF Akt ACTIVITY | SMITHKLINE BEECHAM CORPORATION | 2011-08-11 | — | — | US | disclosed |
| US-20110196009-A1 | INHIBITORS OF Akt ACTIVITY | SMITHKLINE BEECHAM CORPORATION | 2011-08-11 | — | — | US | disclosed |
| WO-2010045309-A1 | INHIBITORS OF AKT ACTIVITY | GLAXOSMITHKLINE LLC (US) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200163939-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, CYP11B1, MCL1 | AKT1 1216/4885AKT2 1329/4885AKT3 1098/4885 |
| US-20110196009-A1 | INHIBITORS OF Akt ACTIVITY | AKT2, AKT1, AKT3 | AKT1 2/4885AKT2 1/4885AKT3 3/4885 |
| US-11135201-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, HCCS, MCL1 | AKT1 1236/4885AKT2 1565/4885AKT3 1286/4885 |
| US-11147800-B2 | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, CYP11B1, MCL1 | AKT1 1216/4885AKT2 1329/4885AKT3 1098/4885 |
| US-20210379021-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | CYP3A43, CYP1A1, UGT1A3 | AKT1 3945/4885AKT2 4183/4885AKT3 4012/4885 |
| US-20200163940-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, HCCS, MCL1 | AKT1 1236/4885AKT2 1565/4885AKT3 1286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.